Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer
Isamu Okamoto(Kyushu University Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Haruyasu Murakami(Shizuoka Cancer Center), Nobuyuki Yamamoto(Wakayama Medical University), Seiji Niho(Dokkyo Medical University), Koichi Azuma(Kyushu University Hospital), Atsushi Horiike(The Cancer Institute Hospital), Yukio Hosomi(Tokyo Metropolitan Komagome Hospital), Tomohiro Ozaki(Kishiwada City Hospital), Shinji Atagi(National Institute of Technology, Nara College), Shogo Nomura(Juntendo University), Hidehito Horinouchi(Tokyo National Hospital), Masahiko Ando(Nagoya University Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Yuichiro Ohe(National Cancer Center), Yuka Fujita, Yasuto Yoneshima(Kyushu University), Hiroaki Okamoto(Yokohama Municipal Citizen's Hospital), Hiroshi Nokihara(Tokushima University Hospital)
Cited by 67
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k